Table 2.
Mean age at diagnosis of each clinical manifestation of FD in patients with the p.F113L mutation.
| Age at diagnosis (years) (Mean ± SD) (Min-Max) |
Fabry patients | Males | Females | p |
|---|---|---|---|---|
| LVH | 61 ± 12 (31–89) | 57 ± 10 (31–78) | 73 ± 8 (57–89) | <0.001 |
| LGE | 60 ± 9 (40–76) | 58 ± 8 (40–76) | 65 ± 8 (46–74) | 0.013 |
| Atrial fibrillation | 70 ± 10 (52–80) | 67 ± 11 (52–78) | 77 ± 3 (74–80) | 0.262 |
| Non-sustained VT | 62 ± 10 (45–77) | 57 ± 8 (45–77) | 70 ± 6 (60–77) | 0.003 |
| RBBB | 64 ± 9 (51–85) | 61 ± 6 (51–78) | 76 ± 9 (62–85) | 0.001 |
| LAFB | 63 ± 11 (42–89) | 60 ± 7 (47–78) | 72 ± 14 (42–89) | 0.003 |
| BB | 66 ± 9 (53–85) | 62 ± 6 (53–78) | 78 ± 6 (71–85) | <0.001 |
| Complete AV block | 63 ± 10 (49–83) | 60 ± 7 (49–71) | 79 ± 6 (75–83) | 0.036 |
| Pacemaker | 65 ± 11 (49–84) | 60 ± 7 (49–71) | 81 ± 5 (75–84) | 0.009 |
| Albuminuria A2 or A3 | 54 ± 14 (18–86) | 55 ± 12 (22–78) | 51 ± 18 (18–86) | 0.222 |
| CKD ≥ G3 | 70 ± 10 (50–86) | 66 ± 10 (50–78) | 75 ± 7 (66–86) | 0.202 |
| Brain WML | 53 ± 15 (18–89) | 53 ± 11 (27–75) | 52 ± 17 (18–89) | 0.912 |
| Stroke | 53 ± 12 (41–71) | 48 ± 5 (42–51) | 59 ± 16 (41–71) | 0.700 |
| Sensorineural deafness | 58 ± 13 (20–88) | 57 ± 12 (20–77) | 59 ± 15 (23–88) | 0.380 |
| Cornea verticillata | 60 ± 8 (43–72) | 59 ± 7 (46–68) | 63 ± 10 (43–72) | 0.238 |
p: Males vs. Females.
p < .05 are marked in bold.
AV, atrioventricular; BB, bifascicular block; CKD, chronic kidney disease; LAFB, left anterior fascicular block; LGE, late gadolinium enhancement; LVH, left ventricular hypertrophy; RBBB, right bundle branch block; VT, ventricular tachycardia; WML, white matter lesions.